Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Review Article
The Pathogenesis, Diagnosis, and Management of Pancreatic Cancer
Lavina Malhotra, Daniel H. Ahn and Mark Bloomston*
Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
- *Corresponding Author:
- Mark Bloomston, MD
Associate Professor of Surgery
Division of Surgical Oncology
The Ohio State University Wexner Medical Center
N924 Doan Hall, 410 W. 10th Avenue
Columbus, Ohio 43210, USA
Tel: 614-293-4583
Fax: 614-366-0003
E-mail: Mark.bloomston@osumc.edu
Received date: March 27, 2015; Accepted date: June 16, 2015; Published date: June 24, 2015
Citation: Malhotra L, Ahn DH, Bloomston M (2015) The Pathogenesis, Diagnosis, and Management of Pancreatic Cancer. J Gastrointest Dig Syst 5:295. doi:10.4172/2161-069X.1000295
Copyright: © 2015 Malhotra L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use distribution and reproduction in any medium; provided the original author and source are credited.
Abstract
Pancreatic cancer is an aggressive and devastating disease accounting for 44,000 new cases per year in US. It is characterized by invasiveness, rapid progression and profound resistance to treatment. The majority of cases are diagnosed above age 65 with about 60% of cases at an advanced stage and 5 year survival less than 10%. Advances in molecular biology have greatly improved our understanding of pathogenesis of pancreatic cancer. Many patients have mutations of K-ras oncogene and various tumor suppressor genes are also investigated. Radical surgery remains the only curative treatment option for pancreatic cancer in early stages. For locally advanced, unresectable and metastatic disease, treatment is palliative, in form of adjuvant or neoadjuvant chemotherapy with or without radiotherapy. Gemcitabine based combinations have essentially failed to provide a substantial prolongation of survival and constitute treatment option only in patients with a good performance status. This article provides an overview of epidemiology, risks factors, molecular genetics, biomarkers, diagnostic modality and evidence based therapeutic options for resectable and palliative options for unresectable disease.
